NCT05663502 Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
| NCT ID | NCT05663502 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AIDS Malignancy Consortium |
| Condition | Anal Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-05-10 |
| Primary Completion | 2030-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-05-10 with a primary completion date of 2030-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.
Eligibility Criteria
Inclusion Criteria: * Participants must be at least 18 years of age * Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as: * classic Kaposi sarcoma * transplant-associated Kaposi sarcoma, * anal cancer, * multicentric Castleman's disease, * Epstein Barr Virus (EBV) -positive lymphoma * plasmablastic lymphoma * Hodgkin's lymphoma. * For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: : * Documentation of HIV diagnosis in the medical record by a licensed health care provider; * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \[e.g., Truvada\], which is exclusionary); * HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating \> 1000 RNA copies/mL; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay. * Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer. * The investigator determines that the participant (or his/her legally authorized representative \[LAR\]) has the ability to provide informed consent and the participant or LAR provides written informed consent.
Contact & Investigator
Jeff Bethony
PRINCIPAL INVESTIGATOR
AIDS Malignancy Consortium
Frequently Asked Questions
Who can join the NCT05663502 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05663502 currently recruiting?
Yes, NCT05663502 is actively recruiting participants. Visit ClinicalTrials.gov or contact AIDS Malignancy Consortium to inquire about joining.
Where is the NCT05663502 trial being conducted?
This trial is being conducted at La Jolla, United States, San Francisco, United States, Washington D.C., United States, Miami, United States and 4 additional locations.
Who is sponsoring the NCT05663502 clinical trial?
NCT05663502 is sponsored by AIDS Malignancy Consortium. The principal investigator is Jeff Bethony at AIDS Malignancy Consortium. The trial plans to enroll 200 participants.